The breast cancer research project led by the University of Helsinki receives a grant from the US Department of Defense
A research project led by the University of Helsinki, in which San Francisco partners at the University of California received a breakthrough grant for a breast cancer research program from the U.S. Department of Defense.
A research project led by the University of Helsinki is promoting research aimed at bringing new MYC-based treatments from the laboratory bench to help patients. metastatic breast cancer. The grant will help advance breast cancer research, but it will also promote collaboration between cancer patient organizations in Europe and California.
Some cancer genes that help cancer grow also create weaknesses in cancer cells that can be exploited with new drugs. In breast cancer, the MYC cancer gene programs cells to grow without a break, but uncontrolled growth also makes MYC, which carries cancer cells, a prey for many different drugs.
Scientists are increasingly better able to find drugs to combat the vulnerabilities caused by such cancer genes, and we hope to be able to create the next generation of cancer drugs that will only kill cancer cells but leave normal cells intact. We still hope that these new drugs will also boost the body’s resistance to cancer. “
Juha Klefström, PhD, Research Director, FICAN Research Professor, University of Helsinki
“Our joint team at the University of Helsinki and UCSF have found that the MYC oncogene is associated with poor breast cancer patient outcomes and resistance to immunotherapy. The breakthrough award allows us to find better treatments to selectively kill high MYC tumor cells. patients with these particularly aggressive and difficult-to-treat MYC-high breast cancers, ”notes research director, Professor Andrei Goga, Ph.D., University of California, San Francisco.
The project is being implemented in close collaboration with patient expert groups in the United States and Finland, and new ways are being sought to communicate science to patients and the public.
“It is great that this important topic is being studied and new treatments are being sought for this deadly disease. Breast cancer is the most common cause of cancer deaths in working-age women,” says Anu Niemi, Director General of the Breast Cancer Association Europa Donna Finland.
This unique project brings together dedicated teams of researchers, physicians, and lawyers to explore the mechanical role of MYC in regulating the anti-tumor immune response and to provide new therapeutic approaches for aggressive breast cancer.